Ipsen and Marengo Therapeutics are expanding a deal to include two trispecific antibody assets that tackle so-called cold tumors, which do not typically respond well
Boehringer Ingelheim officially unveiled fibrosis data from a mid-stage trial of its Zealand Pharma-partnered drug in MASH on Friday, after its liver congress abstract was
Biomea Fusion’s Phase 1/2 covalent menin inhibitor program in diabetes has been placed on full clinical hold due to “possible” drug-related hepatotoxicity. Liver enzyme elevations
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Survodutide, a novel glucagon/GLP-1 receptor dual agonist, improved metabolic dysfunction-associated steatohepatitis (MASH) with no worsening of fibrosis, according to results of a phase II trial.
The popular low-calorie sweetener xylitol was linked to increased cardiovascular and thrombotic risk, a series of experiments showed. Metabolomic studies linked xylitol intake to higher
Up until fairly recently, ruxolitinib (Jakafi) was the only FDA-approved treatment for intermediate- and high-risk myelofibrosis, and thus has been the cornerstone of myelofibrosis treatment
A 15-day course of the antiviral nirmatrelvir-ritonavir (Paxlovid) didn’t improve symptoms of long COVID, according to a randomized controlled trial that was stopped early for
The 5-Cog assessment tool helped improve dementia-related care in primary care patients. 5-Cog tripled the odds that a patient would receive a dementia-related intervention within
An intelligent liver function test platform (iLFT) successfully integrated into one Scottish primary care system reduced unnecessary specialist referrals over a 5-year period, and improved